m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05178
 [1]
Non-coding RNA lnc-H2AFV-1 METTL14  lncRNA       miRNA   circRNA Indirect Enhancement m6A modification IFT80 IFT80 METTL14 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target Intraflagellar transport protein 80 homolog (IFT80)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator H2AZ2 pseudogene 1 (H2AZ2P1) LncRNA View Details
Regulated Target Methyltransferase-like protein 14 (METTL14) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary H2AZ2P1 might be a biomarker that alters m6A modification by regulating the m6A methylases METTL3/METTL14 and FTO and then mediating the downstream target Intraflagellar transport protein 80 homolog (IFT80) to promote HNSCC progression.
Responsed Disease Head and neck squamous carcinoma ICD-11: 2B6E
 Disease Info 
In-vitro Model
 HN4 Clear cell renal cell carcinoma Homo sapiens CVCL_IS30
HN-6 Tongue squamous cell carcinoma Homo sapiens CVCL_8129
WSU-HN30 Pharyngeal squamous cell carcinoma Homo sapiens CVCL_5525
SCC-4 Tongue squamous cell carcinoma Homo sapiens CVCL_1684
SCC-9 Tongue squamous cell carcinoma Homo sapiens CVCL_1685
SCC-25 Tongue squamous cell carcinoma Homo sapiens CVCL_1682
CAL-27 Tongue squamous cell carcinoma Homo sapiens CVCL_1107
In-vivo Model To determine whether lnc-H2AFV-1 overexpression could enhance tumorigenicity in vivo, 1 × 106 HN6 cells stably transduced with LV-lnc-H2AFV-1 or LV-NC were subcutaneously injected into the right and left flanks of six mice.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B6E: Head and neck squamous carcinoma 3 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name OraTest Approved [2]
External Link
TTD: D00DCY
 Compound Name Contusugene ladenovec Phase 3 [3]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
External Link
TTD: D04FYL
 Compound Name INGN-234 Discontinued in Phase 2 [4]
Synonyms
P53 tumor suppressor (topical formulation), Introgen
    Click to Show/Hide
External Link
TTD: D05AHK
References
Ref 1 Long noncoding RNA lnc-H2AFV-1 promotes cell growth by regulating aberrant m6A RNA modification in head and neck squamous cell carcinoma. Cancer Sci. 2022 Jun;113(6):2071-2084. doi: 10.1111/cas.15366. Epub 2022 Apr 22.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 3 ClinicalTrials.gov (NCT00041613) Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate. U.S. National Institutes of Health.
Ref 4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028790)